Current Headlines

  1. JSR Corp. Establishes JSR Life Sciences Division, Names Leader
    4/18/2016

    JSR Corporation recently announced the formation and establishment of its Life Sciences Division, JSR Life Sciences (JLS). The newly formed JLS has been established as a business unit for parent company, Tokyo-based JSR Corporation, a company with more than 50 years of success in material and polymer chemistries including marketing latex and magnetic beads to life sciences and diagnostic companies worldwide.

  2. British Biosimilars Association (BBA) Launches In UK
    4/18/2016

    A new industry body, the British Biosimilars Association (BBA), has been formally launched recently with the sole focus of increasing the understanding and use of biosimilar medicines in the UK.

  3. WuXi AppTec Acquires Crelux
    4/15/2016

    WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has acquired Crelux GmbH, a leading structure based drug discovery provider based in Munich, Germany.

  4. CSafe Continues Global Growth Initiative With New Company In Puerto Rico
    4/14/2016

    CSafe Global forms a new company, opens a new Service Center and welcomes a new Director of Sales in one of the world's foremost pharma production locations.

  5. Regeneron And Intellia Therapeutics Announce Collaboration To Discover And Develop CRISPR/Cas Therapeutics
    4/11/2016

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development.

  6. GE Healthcare Expands European Capabilities To Support Accelerated Biomanufacturing
    4/11/2016

    GE Healthcare’s Life Sciences business recently announced that its European manufacturing and distribution site for sterile liquids has expanded its capabilities to include production of large volumes of buffers, process liquids and cell culture media, and launched a rapid production service for prototype cell culture media and buffers.

  7. RareCyte CTC Liquid Tissue Biopsy Technology Showcased At AACR Annual Meeting
    4/11/2016

    At the upcoming annual meeting of the American Association for Cancer Research (New Orleans, April 16-20, 2016) RareCyte, Inc., its collaborators and customers will be presenting results from five collaborative oncology research projects.

  8. Immune Therapeutics Provides Program Status Update On 'MENK'
    4/11/2016

    Immune Therapeutics, Inc. (OTCQB: IMUN); a clinical-stage international biotechnology company providing immunotherapy solutions for the treatment of diseases, autoimmune diseases, and cancer, announced today it is providing shareholders with a status update of Immune Therapeutics, Inc.'s (IMUN) drug development program in China with long-term partner Hubei Qianjiang Pharmaceutical Co. Ltd (Qianjiang).

  9. Ventures And Mayo Clinic Launch Cell And Gene Therapy Company
    4/11/2016

    Recently, GE Ventures and Mayo Clinic announced the launch of Vitruvian Networks, Inc., an independent platform company committed to accelerating access to cell and gene therapies through advanced, cloud-ready software systems and manufacturing services.

  10. Eli Lilly And AstraZeneca Continue Clinical Trial For Early Alzheimer's
    4/8/2016

    Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced that AMARANTH, a Phase 2/3 study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer's disease, will continue to Phase 3 of the Phase 2/3 seamless trial.